GlaxoSmithKline has announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved for the treatment of COPD in Canada.
GlaxoSmithKline Inc. President Paul Lirette said, “For over forty years, GlaxoSmithKline has been at the forefront of delivering medicines to patients with respiratory diseases. We are committed to responding to patients’ needs and are very pleased to be expanding our respiratory portfolio with the introduction of Breo Ellipta 100/25 mcg once-daily for the treatment of COPD in Canada.”
The company says that it expects the inhaler to be available in Canada by the end of this year. Breo Ellipta was approved in the US in May 2013.
Read the GSK press release.
